Shattuck Labs, Inc. (NASDAQ:STTK) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Shattuck Labs, Inc. (NASDAQ:STTK) have earned an average rating of “Hold” from the seven research firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating on the company. The average 12 month price target among analysts that have covered the stock in the last year is $6.20.

A number of brokerages recently commented on STTK. Piper Sandler assumed coverage on Shattuck Labs in a research note on Wednesday, January 28th. They issued an “overweight” rating and a $15.00 target price for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Shattuck Labs in a report on Thursday, January 22nd. HC Wainwright raised shares of Shattuck Labs from a “neutral” rating to a “buy” rating and set a $6.00 target price on the stock in a research note on Monday, December 1st. Finally, Citigroup increased their price target on shares of Shattuck Labs from $2.00 to $4.00 and gave the stock a “neutral” rating in a research report on Tuesday, January 6th.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Orbimed Advisors LLC bought a new position in shares of Shattuck Labs in the third quarter valued at about $15,072,000. Bank of America Corp DE increased its position in Shattuck Labs by 2,968.2% in the 3rd quarter. Bank of America Corp DE now owns 1,131,888 shares of the company’s stock valued at $2,705,000 after acquiring an additional 1,094,997 shares in the last quarter. Aberdeen Group plc raised its stake in shares of Shattuck Labs by 462.1% in the fourth quarter. Aberdeen Group plc now owns 531,177 shares of the company’s stock worth $1,939,000 after acquiring an additional 436,673 shares during the last quarter. Two Sigma Investments LP lifted its position in shares of Shattuck Labs by 431.1% during the third quarter. Two Sigma Investments LP now owns 408,598 shares of the company’s stock worth $977,000 after purchasing an additional 331,664 shares in the last quarter. Finally, Jane Street Group LLC grew its stake in shares of Shattuck Labs by 2,510.8% during the second quarter. Jane Street Group LLC now owns 289,671 shares of the company’s stock valued at $229,000 after purchasing an additional 278,576 shares during the last quarter. 58.74% of the stock is currently owned by institutional investors and hedge funds.

Shattuck Labs Stock Performance

Shares of STTK opened at $3.85 on Thursday. The company has a 50-day simple moving average of $3.63 and a 200-day simple moving average of $2.33. Shattuck Labs has a 52 week low of $0.69 and a 52 week high of $4.89. The firm has a market capitalization of $243.63 million, a P/E ratio of -3.77 and a beta of 1.52.

Shattuck Labs (NASDAQ:STTK) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.01. The firm had revenue of $1.00 million for the quarter. As a group, equities analysts forecast that Shattuck Labs will post -1.48 earnings per share for the current year.

Shattuck Labs Company Profile

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.